ziv-aflibercept

{
  "id": "MLC-T-ONC-009486",
  "term": "ziv-aflibercept",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with other drugs to treat colorectal cancer that has spread to other parts of the body and has not gotten better with other chemotherapy. It is also being studied in the treatment of other types of cancer. Ziv-aflibercept blocks a protein called VEGF, which may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent. Also called vascular endothelial growth factor trap, VEGF Trap, and Zaltrap.",
    "A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression."
  ],
  "synonyms": [
    "vascular endothelial growth factor trap",
    "VEGF Trap",
    "Zaltrap",
    "aflibercept",
    "VEGF Trap R1R2",
    "AVE0005"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ziv-aflibercept/"
}